Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Proteases >  Proteasome inhibitors >  ONX-0914

ONX-0914

Basic information Safety Supplier Related

ONX-0914 Basic information

Product Name:
ONX-0914
Synonyms:
  • ONX 0914
  • PR 957
  • PR 957(ONX 0914)
  • ONX-0914 (PR-957)
  • ONX 0914; ONX0914; ONX-0914; PR-957
  • PR-957;ONX 0914;ONX0914;PR957;PR 957
  • ONX 0914; ONX0914; ONX-0914; PR957; PR-957; PR 957
  • N-[2-(4-Morpholinyl)acetyl]-L-alanyl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-tyrosinamide
CAS:
960374-59-8
MF:
C31H40N4O7
MW:
580.67
Product Categories:
  • Inhibitors
Mol File:
960374-59-8.mol
More
Less

ONX-0914 Chemical Properties

Melting point:
>70oC (dec.)
storage temp. 
Refrigerator
solubility 
DMSO (Slightly), Methanol (Slightly)
form 
Solid
color 
White to Pale Yellow
More
Less

ONX-0914 Usage And Synthesis

Uses

ONX 0914 is a proteosome inhibitor known for treatming malignancies and more recently, effacaciously inducing apoptosis for cancers. Used in the treatment of autoimmune diseases.

Biological Activity

onx-0914, previously known as pr-975, is a potent inhibitor of immunoproteasome, a form of proteasome generating peptides presented on major histocompatibility complex (mhc) class i molecule to cytotixic t cells, which selectively induces conformational changes in the s1 binding pocket of the immunoproteasome subunit β5i (low molecular mass polypeptide 7/lmp7) rather than the constitutive proteasome subunit β5 in human and mouse cells. onx-0914 is able to block the production of proinflammatory cytokines from human peripheral blood mononuclear cells (pbmcs), activate mouse splenocytes, inhibit il-17-producing t cells under th17-polarizing cytokines in vitro, and attenuate disease progression of diabetes, arthritis, and colitis in mouse models.denise niewerth, niels e. franke, gerrit jansen, yehuda g. assaraf, johan van meerloo, christopher. kirk, jeremiah degenhardt, janet anderl, aaron d. schimmer, sonja zweegman, valerie de haas, terzah m. horton, gertjan j.l. kaspers, and jacqueline cloos. higer ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. haematologica 2013.khalid w. kalim, michael basler, christopher j. kirk and marcus groettrup. immunoproteasome subunit lmp7 deficiency and inhibition suppresses th1 and th17 but enhances regulatory t cell differentiation. j immunol 2012; 189:4182-4193

Enzyme inhibitor

This potent protease inhibitor (FW = 580.67 g/mol; CAS 960374-59-8; Solubility: 100 mg/mL DMSO or H2O), also known as PR-957 and N-[2-(4- morpholinyl)acetyl]-L-alanyl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2- oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-tyrosinamide, targets (IC50 = 10 nM) the chymotrypsin-like protease activity of immunoproteasomes, a distinct class of proteasome found mainly in monocytes and lymphocytes. These specialized proteasomes shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I). ONX-0914 shows minimal cross-reactivity for the constitutive proteasome. Selective inhibition blocks production of Interleukin-23 (IL-23) by activated monocytes and interferon-γ and IL-2 by T cells.

target

LMP7

ONX-0914Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 17702719238
Email
sales@sun-shinechem.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
More
Less